NCT05796388View on ClinicalTrials.gov

A Study of Virtual Reality and Linaclotide for IBS-C

NARecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Irritable Bowel Syndrome with Constipation
Interventions
DEVICE

Virtual Reality

Both groups will receive standard of care linaclotide 290 mcg.

Trial Locations (1)

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Cedars-Sinai Medical Center

OTHER

collaborator

AbbVie

INDUSTRY

collaborator

Ironwood Pharmaceuticals, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER